<DOC>
	<DOCNO>NCT00952705</DOCNO>
	<brief_summary>The purpose study show quadrivalent live attenuate influenza vaccine ( Q/LAIV-BFS ; MEDI8662 ) least immunogenic two different form commercial vaccine , FluMist , compare strain-specific antibody level blood .</brief_summary>
	<brief_title>A Study Evaluate Immunogenicity Quadrivalent LAIV ( MEDI8662 ) Adults 18 49 Years Age</brief_title>
	<detailed_description>The primary objective study determine immunologic noninferiority MEDI8662 , quadrivalent live attenuate influenza vaccine ( Q/LAIV ) ( deliver intranasally use blow-fill-seal [ BFS ] delivery system ) ( Q/LAIV-BFS ) two trivalent formulation license FluMist ( deliver intranasally use Becton Dickinson [ BD ] Accuspray™ device ) compare strain-specific geometric mean titer ( GMTs ) post dosing .</detailed_description>
	<criteria>Male female , age 18 49 year , inclusive ( reach 18th year birthday yet reach 50th year birthday ) time randomization Females childbearing potential , must use effective method avoid pregnancy 30 day prior first dose investigational product , must agree continue use precaution 60 day dose investigational product . In addition , participant must also negative urine blood pregnancy test screening , screen Day 0 occur day , day vaccination prior randomization . Healthy medical history physical examination OR presence stable underlie chronic medical condition hospitalization require previous year Acute illness evidence significant active infection randomization Fever great equal 100.4 degree F ( 38°C ) randomization History asthma Any drug therapy 15 day prior randomization expect drug therapy 30 day post dose exception contraceptive ; topical corticosteroid antifungal uncomplicated dermatitis ; chronic medication ( include take asneeded basis ) well tolerate initiate and/or dosage change within 90 day randomization Previous medical history evidence intercurrent illness may compromise safety participant study Current expect receipt immunosuppressive medication ( inhaled topical corticosteroid topical calcineurin inhibitor permit ) within 30day window around dose Receipt immunoglobulin blood product within 90 day randomization study expect receipt study participation Receipt investigational drug therapy within 30 day prior randomization plan receipt investigational drug therapy 30 day dose investigational product ( use license agent indication list package insert permit ) Receipt nonstudy vaccine within 30 day prior randomization plan receipt nonstudy vaccine 30 day dose Receipt influenza vaccine ( investigational license ) 2009 prior randomization anticipate receipt prior collection postdose immunogenicity blood sample study Any known immunosuppressive condition immune deficiency disease include know suspected infection human immunodeficiency virus ( HIV ) History allergic disease reaction likely exacerbate component Q/LAIVBFS include allergy egg , egg protein , gentamicin , gelatin , serious , life threatening , severe reaction previous influenza vaccination History GuillainBarré syndrome Use antiviral agent activity influenza virus ( include amantadine , rimantadine , oseltamivir zanamivir ) within 30 day prior receipt investigational product anticipate use within 30 day receipt investigational product Known suspect mitochondrial encephalomyopathy Pregnant lactate female Any condition , opinion investigator , would interfere evaluation investigational product interpretation participant safety study result Participant , legal guardian , immediate family member participant employee clinical study site otherwise involved conduct study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>